Could changing when chemo is given boost cancer treatment success?
NCT ID NCT06052839
Summary
This study is testing whether changing the timing and frequency of chemotherapy given alongside an immunotherapy drug (pembrolizumab) might work better for people with advanced head and neck cancer that has returned or spread. Researchers think the current standard schedule might weaken the immune system, so they are trying a new approach where chemotherapy is given less often and starts after the immunotherapy. The main goal is to see if more patients are alive and without their cancer getting worse after 6 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.